Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $82
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raised the price target from $81 to $82.
July 18, 2023 | 8:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has maintained a Strong Buy rating on Mirum Pharmaceuticals and raised the price target from $81 to $82.
The news of Raymond James maintaining a Strong Buy rating and raising the price target for Mirum Pharmaceuticals is likely to have a positive impact on the company's stock in the short term. This is because such ratings and price target adjustments often influence investor sentiment and can lead to increased buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100